Mirna inhibitor for the treatment of bone loss diseases
A miR-1246 inhibitor addresses the limitations of current bone loss disease treatments by specifically targeting miR-1246 to reduce osteoclast activity, effectively inhibiting bone resorption and promoting normal bone remodeling.
Patent Information
- Application Number
- PCT/IT2024/050186
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-20
- Filing Date
- 2024-09-18
- Publication Date
- 2025-03-27
AI Technical Summary
Current treatments for bone loss diseases, such as bisphosphonates and Denosumab, have side effects like frozen bone and osteonecrosis, and there is a need for new therapeutic approaches that can effectively inhibit osteoclast differentiation and activity without these drawbacks.
The use of a microRNA inhibitor specifically targeting miR-1246, which is upregulated during osteoclast differentiation, to reduce osteoclast hyper-activation and restore physiological bone remodeling in bone loss diseases.
The miR-1246 inhibitor effectively reduces osteoclast differentiation and activity, thereby inhibiting bone resorption and restoring normal bone remodeling, offering a potential treatment for bone loss diseases without the side effects of existing therapies.